RSS Feed
July 19th, 2012 
FAKE NEWS for the Zionist agenda Previous Post: Spain royal family follows public sector wage cut nbsp
Novo faces new hurdle in long-acting insulin race
Reuters – Novo Nordisk’s bid to challenge Sanofi’s dominance of the long-lasting insulin market hit another snag after U.S. regulators delayed approval of the Danish drugmaker’s degludec until after an expert review. Novo has said degludec could become a blockbuster – defined by the industry as a treatment that generates more than $1 billion in sales within five years of its launch. But some analysts see the drug with peak sales potential as high as the current $5 billion for Sanofi’s top-selling Lantus. Read article
Tags: nature of corporations, pharmaceuticals
Related posts:
Is too much exercise dangerous for your heart?
As TVs struggle, new Panasonic chief prepares thorough review
4 Tips to Protect Your Small Business Against Cyberattacks
Today's Kids May Be Destined for Adult Heart Disease
Minnesota Waitress Sues After Police Seize $12,000 ‘Tip’
Another Bait and Switch? Obama Opposes CISPA. Yeah, Right
Posted in 
Tags: 
